Olmibite Beta 25 Tablet ER
Images are for reference. Actual packaging may vary.
Olmesartan Medoxomil (20mg) + Metoprolol Succinate (25mg)
1 units • Other
A valid prescription is required for this medicine.
Haven’t found an alternative? A health advisor can help you understand what to do next.
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
+1 more active ingredient
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmibite Beta 25 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 25 mg, formulated as an extended-release tablet. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The combination of these agents provides complementary mechanisms to effectively manage hypertension, reducing the risk of cardiovascular morbidity and mortality.
Olmibite Beta 25 Tablet ER is indicated for the treatment of essential hypertension in patients who require dual therapy for optimal blood pressure control. The extended-release formulation ensures sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. Caution is advised in patients with bradycardia, heart block, severe hepatic impairment, or asthma.
Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This medication should be used under medical supervision with consideration of individual patient risk factors.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Side-effect information is not available for this medicine. Please consult your doctor or pharmacist.
Olmibite Beta 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmibite Beta 25 Tablet ER is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Olmibite Beta 25 Tablet ER should be used with caution in patients with severe kidney disease. Dose adjustment of Olmibite Beta 25 Tablet ER may be needed. Please consult your doctor. Regular monitoring of blood pressure is advisable for dose adjustment.
Exercise Caution
Olmibite Beta 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Olmibite Beta 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Olmibite Beta 25 Tablet ER may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Olmibite Beta 25 Tablet ER






